The move is the latest recruiting win for RBC Wealth Management as it continues to lure top talent away from big banks and brokerage firms.

J.P. Morgan analyst Anthony Paolone maintained a Buy rating on W. P. Carey Inc. (WPC – Research Report) on January 16 and set a price target of

In a report released today, Javier Garrido from J.P. Morgan maintained a Hold rating on Orsted (DOGEF – Research Report), with a price target

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his company to go after larger deals.

NFJ Investment Group CIO John Mowrey reacts to real estate giant Brookfield defaulting on $161 million mortgage for office properties on 'The Claman Countdown.' Carnivore Trading CEO Dutch Masters and Prosper Trading Academy CEO Scott Bauer discuss whether banking anxieties are overblown on 'The Claman Countdown.

Doug Petno, Troy Rohrbaugh and Marianne Lake are the three top contenders to succeed JPMorgan Chase CEO Jamie Dimon, according to a report.

SmartCentres Real Estate Investment Trust ("SmartCentres" or the "Trust") announced today that it has priced an offering of $300 million aggregate principal amount of 4.737% Series AB senior unsecured debentures on an agency basis.

On Thursday, RBC Capital Markets adjusted its outlook on shares ... With a market capitalization of $709.92 billion and a P/E ratio of 12.93, JPM has maintained dividend payments for 55 ...

J.P. Morgan analyst Olivia Townsend maintained a Buy rating on adidas AG (0OLD – Research Report) today and set a price target of €275.00. The

Underperforming since the calendar turned, "munis have continued to cheapen over the past three weeks as Treasury returns are about flat for the year while munis are down 0.31%," said Jason Wong, vice president of municipals at AmeriVet Securities.

Stifel analysts adjusted their outlook on Inspire Medical Systems (NYSE:INSP), reducing the price target to $190 from the previous $200 while maintaining a Hold rating on the stock. The revision follows a period of fluctuating stock performance and a recent presentation by the company's management.

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price target of